Discovery of a new class of integrin antibodies for fibrosis
Open Access
- 22 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-15
- https://doi.org/10.1038/s41598-021-81253-0
Abstract
Lung fibrosis, or the scarring of the lung, is a devastating disease with huge unmet medical need. There are limited treatment options and its prognosis is worse than most types of cancer. We previously discovered that MK-0429 is an equipotent pan-inhibitor of αv integrins that reduces proteinuria and kidney fibrosis in a preclinical model. In the present study, we further demonstrated that MK-0429 significantly inhibits fibrosis progression in a bleomycin-induced lung injury model. In search of newer integrin inhibitors for fibrosis, we characterized monoclonal antibodies discovered using Adimab’s yeast display platform. We identified several potent neutralizing integrin antibodies with unique human and mouse cross-reactivity. Among these, Ab-31 blocked the binding of multiple αv integrins to their ligands with IC50s comparable to those of MK-0429. Furthermore, both MK-0429 and Ab-31 suppressed integrin-mediated cell adhesion and latent TGFβ activation. In IPF patient lung fibroblasts, TGFβ treatment induced profound αSMA expression in phenotypic imaging assays and Ab-31 demonstrated potent in vitro activity at inhibiting αSMA expression, suggesting that the integrin antibody is able to modulate TGFβ action though mechanisms beyond the inhibition of latent TGFβ activation. Together, our results highlight the potential to develop newer integrin therapeutics for the treatment of fibrotic lung diseases.This publication has 54 references indexed in Scilit:
- Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptorThe Journal of cell biology, 2012
- Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8–mediated activation of TGF-βJCI Insight, 2011
- Anti-integrin monoclonal antibodiesJournal of Cell Science, 2009
- Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma MultiformeClinical Cancer Research, 2008
- αvβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport MouseThe American Journal of Pathology, 2007
- Dual Functionality of the Anti-β1 Integrin Antibody, 12G10, Exemplifies Agonistic Signalling from the Ligand Binding Pocket of Integrin Adhesion ReceptorsOnline Journal of Public Health Informatics, 2005
- αv integrins play an important role in myofibroblast differentiationWound Repair and Regeneration, 2004
- Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of OsteoporosisJournal of Medicinal Chemistry, 2003
- Integrins: Bidirectional, Allosteric Signaling MachinesCell, 2002
- Identification of a novel anti‐integrin monoclonal antibody that recognises a ligand‐induced binding site epitope on the β1 subunitFEBS Letters, 1995